NasdaqGM:KYMRBiotechs
Kymera Therapeutics (KYMR) TTM Loss Of US$311 Million Tests Bullish Growth Narrative
Kymera Therapeutics (KYMR) closed FY 2025 with Q4 revenue of US$2.9 million and a basic EPS loss of US$0.97, while full year trailing twelve month figures showed revenue of US$39.2 million and a basic EPS loss of US$3.69. The company reported a decline in quarterly revenue from US$22.1 million in Q1 2025 to US$2.9 million in Q4, while basic EPS losses ranged between US$0.82 and US$0.97 across the year. This has set up a results season in which investors are weighing growth potential against...